Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. Fujii T, et al. Among authors: cheng yc. Breast Cancer Res Treat. 2021 Sep;189(2):455-461. doi: 10.1007/s10549-021-06276-7. Epub 2021 Jun 15. Breast Cancer Res Treat. 2021. PMID: 34131830
Prognostic value of nodal ratios in node-positive breast cancer.
Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Woodward WA, et al. Among authors: cheng yc. J Clin Oncol. 2006 Jun 20;24(18):2910-6. doi: 10.1200/JCO.2005.03.1526. J Clin Oncol. 2006. PMID: 16782931 Review.
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. Cheng YC, et al. Biol Blood Marrow Transplant. 2004 Nov;10(11):794-804. doi: 10.1016/j.bbmt.2004.07.009. Biol Blood Marrow Transplant. 2004. PMID: 15505610 Free article. Clinical Trial.
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Cheng YC, et al. Int J Hematol. 2009 Dec;90(5):627-634. doi: 10.1007/s12185-009-0439-6. Epub 2009 Dec 9. Int J Hematol. 2009. PMID: 19998065 Clinical Trial.
1,547 results